Immutep Ltd. Files Routine 6-K Disclosure

Ticker: PRRUF · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1506184

Immutep Ltd 6-K Filing Summary
FieldDetail
CompanyImmutep Ltd (PRRUF)
Form Type6-K
Filed DateSep 3, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory-filing, foreign-private-issuer

TL;DR

IMMUTEP files routine 6-K, no major news, just compliance.

AI Summary

Immutep Ltd. filed a Form 6-K on August 29, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based in Sydney, Australia, and operates in the pharmaceutical preparations sector. This filing does not contain specific financial figures or operational updates but serves as a routine disclosure.

Why It Matters

This filing indicates Immutep Ltd. is fulfilling its disclosure obligations as a foreign private issuer, which is important for investors tracking regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information, thus posing minimal immediate risk.

Key Players & Entities

  • IMMUTEP Ltd (company) — Registrant
  • Prima BioMed Ltd (company) — Former company name
  • August 29, 2025 (date) — Date of report
  • Sydney, Australia (location) — Company headquarters

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is for IMMUTEP Limited to report its status as a foreign private issuer and fulfill its disclosure obligations under the Securities Exchange Act of 1934.

When was this Form 6-K filed?

This Form 6-K was filed on August 29, 2025.

What is IMMUTEP Limited's former company name?

IMMUTEP Limited's former company name was Prima BioMed Ltd.

Where is IMMUTEP Limited's principal executive office located?

IMMUTEP Limited's principal executive office is located at Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia.

Does IMMUTEP Limited file its annual reports under Form 20-F or Form 40-F?

IMMUTEP Limited indicates that it files its annual reports under Form 20-F.

Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 16.8 · Accepted 2025-09-02 18:09:01

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 29, 2025 IMMUTEP LIMITED By: /s/ Marc Voigt Name: Marc Voigt Title: Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.